116 related articles for article (PubMed ID: 38546696)
1. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Garderet L; Gras L; Koster L; De Wreede L; Montserrat R; Vincent L; Fenk R; Karunanithi K; Deeren D; Kaufmann M; Kuball J; Ozdogu H; Cascon MJP; Passweg J; Rye A; Salmenniemi U; Snowden J; Hansen CT; Leleu X; Gastaud L; Sokolowska JD; Raj K; Beksac M; Schönland S; Hayden P; McLornan D
Haematologica; 2024 Mar; ():. PubMed ID: 38546696
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.
Waszczuk-Gajda A; Gras L; de Wreede LC; Sirait T; Illes A; Ozkurt ZN; Snowden JA; Arat M; Bulabois CE; Niederland J; Sever M; Paneesha S; Potter V; Gadisseur A; Chalopin T; Van Gorkom G; López JM; Kerre T; Drozd-Sokolowska J; Raj K; Hayden PJ; Beksac M; Yakoub-Agha I; McLornan DP; Schönland S
Bone Marrow Transplant; 2023 Apr; 58(4):424-429. PubMed ID: 36681775
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
Christopeit M; Labopin M; Gorin NC; Saraceni F; Passweg J; Forcade E; Maertens J; Van Lint MT; Bosi A; Niederwieser D; Ehninger G; Polge E; Mohty M; Nagler A
Am J Hematol; 2018 Dec; 93(12):1532-1542. PubMed ID: 30218444
[TBL] [Abstract][Full Text] [Related]
5. HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA - ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA.
Cheng Kiat Ng L; Shwei Wen Tham C; Wei Inng Lim F; Chen Y; Yeu Ong S; Nagarajan C; Lee JJ; Tee Goh Y; Linn YC; Shan Lee Y; Diong Phipps C; Kim Siang Quek J; Hein T; Cheng Hwang JC; Grigoropoulos N; Khee Hwang WY; Yew Leng Ho A
Blood Cell Ther; 2021 Nov; 4(4):92-100. PubMed ID: 36714065
[TBL] [Abstract][Full Text] [Related]
6. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
8. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
[TBL] [Abstract][Full Text] [Related]
9. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Czerw T; Pabst T; Blaise D; Dumas PY; Nemet D; Arcese W; Trisolini SM; Wu D; Huynh A; Zuckerman T; Meijer E; Cagirgan S; Cornelissen J; Houhou M; Polge E; Mohty M; Nagler A
Cancer; 2017 Mar; 123(5):824-831. PubMed ID: 27906458
[TBL] [Abstract][Full Text] [Related]
12. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
14. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study.
Kim Y; Park SS; Jeon YW; Yahng SA; Shin SH; Min CK;
Transplant Cell Ther; 2023 Jan; 29(1):55.e1-55.e9. PubMed ID: 36202336
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.
Cook G; Liakopoulou E; Pearce R; Cavet J; Morgan GJ; Kirkland K; Lee J; Davies FE; Hall R; Rahemtulla A; Russell N; Marks DI;
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1638-45. PubMed ID: 21565277
[TBL] [Abstract][Full Text] [Related]
16. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy.
Huang Z; Li Z; Wang J; Gui R; Zu Y; Yu F; Lin Q; Zhao H; Zhang Y; Fang B; Liu Y; Zhou K; Li Y; Fu Y; Yao Z; Song Y; Zhou J
Front Oncol; 2023; 13():1162413. PubMed ID: 37256185
[TBL] [Abstract][Full Text] [Related]
18. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.
Hsu TL; Tsai CK; Liu CY; Yeh CM; Lin FL; Hsiao LT; Liu YC; Chien SH; Wang HY; Ko PS; Lin TA; Chen WC; Chen PM; Liu JH; Gau JP; Liu CJ
Ann Hematol; 2024 Mar; ():. PubMed ID: 38472362
[TBL] [Abstract][Full Text] [Related]
20. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT.
Bento L; Boumendil A; Finel H; Khvedelidze I; Blaise D; Fegueux N; Castagna L; Forcade E; Chevallier P; Mordini N; Brice P; Deconinck E; Gramatzki M; Corradini P; Hunault M; Musso M; Tsoulkani A; Caballero D; Nati S; Montoto S; Sureda A;
Bone Marrow Transplant; 2021 Mar; 56(3):655-663. PubMed ID: 33046830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]